屈昔多巴 T2547

Product Introduction
Bioactivity


英文名: Droxidopa

描述: Droxidopa (L-DOPS) 是 Droxidopa (w/w80%) 和 Pharmaceutical starch (w/w20%) 的混合物，能透过血脑屏障，可作为神经递质去甲肾上腺素和肾上腺素的原药。

体内活性: Droxidopa通过口服给药,吸收后通过酶多巴脱羧酶转化为去甲肾上腺素,与内源性去甲肾上腺素共同增加神经递质水平。Droxidopa也可以穿过血脑屏障（BBB）,并在脑内转化为去甲肾上腺素和肾上腺素。

存储条件: Powder: -20°C for 3 years | In solvent: -80°C for 1 year

溶解度: DMSO : 2.13 mg/ml (10 mM)
H2O : 1.25mM


关键字: Adrenergic Receptor | orally active | Inhibitor | Beta Receptor | inhibit | neurogenic orthostatic hypotension | SM-5688 | ADHD | blood pressure | SM 5688 | Droxidopa

相关产品: L748337 | Tizanidine | DL-071-IT | Fargesin | Rotigotine- | nifenalol.HCl | Naftopidil hydrochloride | Nicardipine hydrochloride | Moxisylyte hydrochloride | 5-HT1A modulator 1

相关库: Drug Repurposing Compound Library | Anti-Neurodegenerative Disease Compound Library | Approved Drug Library | Anti-Cancer Drug Library | Membrane Protein-targeted Compound Library | Human Metabolite Library | Anti-Cancer Clinical Compound Library | GPCR Compound Library | Anti-Cancer Approved Drug Library | Orally Active Compound Library

屈昔多巴 T2547信息由TargetMol中国为您提供，如您想了解更多关于屈昔多巴 T2547报价、型号、参数等信息，欢迎来电或留言咨询。

注：该产品未在中华人民共和国食品药品监督管理部门申请医疗器械注册和备案，不可用于临床诊断或治疗等相关用途